Study points to need for Group B Strep vigilance in newborns

03/21/2013 | Minnesota Public Radio

Health experts in Minnesota are expressing concern regarding an increase in cases of a drug-resistant form of Group B Streptococcus called serotype IV. The strain made up 16% of neonatal cases in 2010, according to a study published in the CDC journal Emerging Infectious Diseases. Researcher Dr. Patricia Ferrieri highlighted the importance of watching for signs of drug-resistant Group B Strep in an infant's first days of life.

View Full Article in:

Minnesota Public Radio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC